menu

T-Cell Therapy Market

Schedule Call

T-Cell Therapy Market

T-Cell Therapy Market by Type (CAR T-Cell Therapy, TCR Based), Modality (Research, Commercialized), Indication (Hematologic Malignancies, Solid Tumors) – Global Outlook & Forecast 2022-2030

GR - 155695 Category: Pharmaceuticals

Number of pages: 100  |  Report Format: PDF  |  Published date: 15 February, 2023

Historical Years – 2020  |  Base Year – 2021  |  Forecasted Years – 2022-2030


T-Cell Therapy Market Scope

Report Attribute

Details

Market size value in 2021

US$ 5.3 billion

Revenue forecast in 2030

US$ 25 billion

Growth Rate

CAGR of 19.1% from 2022 to 2030

Base year for estimation

2021

Forecast period

2022-2030

Historical Year

2020

Segments covered

Type, Modality, Indication, and Region

Regional scope

North America, Europe, Asia Pacific, and the Rest of the World (ROW)

Report Overview

According to the deep-dive market assessment study conducted by Growth+ Reports, the global t-cell therapy market was valued at US$ 5.3 billion in 2021. The market is expected to witness a CAGR of 19.1% from 2022 to 2030. 

Market Fundamentals

T-cell therapy, also known as T-cell immunotherapy, is a type of cancer treatment that harnesses the power of the body's own immune system to fight cancer cells. T-cells are a type of white blood cell that play a crucial role in the immune system's ability to recognize and destroy cells that are foreign or abnormal, such as cancer cells. T-cell therapy works by collecting T-cells from a patient's blood, modifying them in a laboratory to recognize and attack specific cancer cells, and then infusing the modified T-cells back into the patient's bloodstream. The modified T-cells then work to destroy the cancer cells and continue to multiply and persist in the body, providing ongoing protection against cancer recurrence. 

The T-cell therapy market is a rapidly growing field within the larger immunotherapy market, driven by advances in cancer research and the increasing recognition of the potential benefits of T-cell-based treatments. T-cell therapy has shown promising results in the treatment of various types of cancer, including lymphoma and leukemia, and is being explored for the treatment of other diseases, including solid tumors and autoimmune disorders. The market for T-cell therapy is expected to continue growing in the coming years, driven by factors such as the technological advances, and growing investment and research and development efforts. Despite the positive outlook for the T-cell therapy market, the high cost of these treatments and the potential for side effects and other safety concerns remain challenges. Efforts to reduce costs and improve access to T-cell therapy for more patients will be an important factor in the continued growth of the market.

[576576]

Market Dynamics 

The increasing incidence of cancer worldwide, particularly in developed countries, is driving demand for new and effective cancer treatments, including t-cell therapy. According to GLOBOCAN 2020 report around 19 million new cases of cancer were detected in 2020. The t-cell therapy market has seen a significant increase in investment, as well as research and development efforts, as companies and organizations aim to bring new and more effective treatments to market which is boosting the growth of the t-cell therapy market. T-cell therapy is being explored for the treatment of a growing number of cancer types and other diseases, including solid tumors and autoimmune disorders, leading to a wider range of potential patients and a growing t-cell therapy market. As t-cell therapy continues to gain recognition as a promising treatment option, regulatory agencies, such as the US FDA, are increasing their focus on the development and approval of T-cell therapies, further driving the growth of the t-cell therapy market. Moreover, the t-cell therapy market is driven by technological advancements, including improvements in cell manufacturing processes, the development of new delivery methods, and the discovery of new target antigens. Additionally, the growing recognition of T-cell therapy as a promising treatment option for cancer is driving increased interest and investment in the field, leading to the development of new and improved treatments. However, the high cost related to the t-cell therapy is restricting the t-cell therapy market growth. The t-cell therapy is still in its early stages of development, and as a result, is only available in a limited number of centers worldwide and there are some side effects related to the therapy thus these factors are also hampering the growth of the global t-cell therapy market.

Market Ecosystem

The global t-cell therapy market has been analyzed from four perspectives: Type, Modality, Indication, and Region

T-Cell Therapy Market by Type

[8756757]

The market for t-cell therapy is segmented based on type into CAR t-cell therapy, t-cell receptor (TCR)-based, tumor infiltrating lymphocytes (TIL)-based. The CAR t-cell therapy segment dominated the global t-cell therapy market in 2021. CAR T-cell therapy has demonstrated remarkable efficacy in the treatment of various types of cancer, including lymphoma and leukemia, which has helped to establish its position as a leading T-cell therapy. CAR T-cell therapy has received regulatory approvals in several countries, including the US, Europe, and China, which has helped to increase patient access to these treatments and has contributed to its dominance in the market. The growing demand for immune-based therapies for cancer treatment has driven increased interest and investment in CAR T-cell therapy, helping to establish its dominant position in the T-cell therapy market. The growing body of clinical evidence supporting the safety and efficacy of CAR T-cell therapy has helped to establish its dominant position in the T-cell therapy market and has driven increased patient demand for these treatments.

T-Cell Therapy Market by Modality 

Based on modality, the global t-cell therapy market is divided into research and commercialized. The research segment had the largest share of the t-cell therapy market in 2021. The increasing demand for immune-based therapies for cancer treatment has driven significant research efforts in T-cell therapy, particularly in the development of new and improved treatments. The continuous advancements in T-cell therapy technology, such as the development of CAR T-cell therapy, have driven increased interest and investment in T-cell therapy research, helping to establish the research segment as a dominant player in the market. The high unmet need for effective cancer treatments has driven increased investment and research efforts in T-cell therapy, as it has the potential to offer a new and effective approach to cancer treatment.

T-Cell Therapy Market by Indication

Based on indication, the global t-cell therapy market is segmented into hematologic malignancies, solid tumors, and others. The hematologic malignancies segment had the significant share of the t-cell therapy market in 2021. The hematologic malignancies is further sub-segmented into lymphoma, leukemia, and myeloma. Hematologic malignancies, such as leukemia and lymphoma, are some of the most common types of cancer, which has driven increased demand for effective treatments and has helped to establish the hematologic malignancies segment as a dominant player in the T-cell therapy market. According to GLOBOCAN 2020 report about 474,519 which is ~ 2.6% of all cancer cases are of leukemia. There is a growing body of clinical evidence supporting the safety and efficacy of T-cell therapy in the treatment of hematologic malignancies, which has helped to drive increased patient demand for these treatments and has contributed to the dominance of the hematologic malignancies segment in the T-cell therapy market. T-cell therapy, particularly CAR T-cell therapy, has demonstrated remarkable efficacy in the treatment of hematologic malignancies, which is boosting the segmental growth. 

T-Cell Therapy Market by Region

Based on region, the global t-cell therapy market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America dominated the global t-cell therapy market in 2021, followed by Europe and Asia Pacific. The North American region has a high prevalence of cancer, which has driven increased demand for effective cancer treatments and has helped to support the growth of the T-cell therapy market. According to the American Cancer Society in U.S. there is an estimated 1.9 million new cancer cases diagnosed in 2022. The North American region has a strong healthcare infrastructure, which has helped to support the growth of the T-cell therapy market by providing the necessary infrastructure and resources to support research and development efforts, as well as patient access to these treatments.There has been a growing awareness of T-cell therapy, including CAR T-cell therapy, among patients and healthcare providers in North America, which has helped to increase demand for these treatments and has driven growth in the T-cell therapy market.

Competitive Landscape

Some of the prominent players operating in the t-cell therapy market are: 

Strategic Developments 

  • In February 2023, Kite, a Gilead Company announced the three years follow up results from the pivotal ZUMA-3 study of the CAR T-cell therapy Tecartus (brexucabtagene autoleucel). The investigation's findings, which included a median overall survival (OS) of 26 months and a stable safety profile since the two-year analysis, showed that responses remained persistent in individuals with relapsed/refractory B-cell acute lymphoblastic leukaemia (R/R B-ALL).
  • In February 2023, Celyad Oncology announced the publication of the data from the haematological arm of the THINK study which evaluated CYAD-01 in relapsed or refractory (r/r) acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS) or multiple myeloma (MM) patients. In the dose escalation portion of the research, which examined three dose levels of CYAD-01 using a regimen of three infusions at two-week intervals in the absence of any preconditioning chemotherapy, data from the 16 patients who received CYAD-01 treatment are included in the paper. Three of the 12 evaluable AML/MDS patients demonstrated an objective response, and overall, CYAD-01 demonstrated favorable safety data and evidence of therapeutic efficacy.
  • In June 2022, Bristol Myers Squibb received FDA approval for Breyanzi (lisocabtagene maraleucel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B.

Frequently Asked Questions About This Report

T-cell therapy, also known as T-cell immunotherapy, is a type of cancer treatment that harnesses the power of the body's own immune system to fight cancer cells. T-cells are a type of white blood cell that play a crucial role in the immune system's ability to recognize and destroy cells that are foreign or abnormal, such as cancer cells

The prominent players operating in the global t-cell therapy market are Novartis AG; Merck KGaA; Gilead Sciences Inc.; Bristol-Myers Squibb Company; Pfizer Inc.; TCR2 Therapeutics Inc.; Amgen, Inc.; Bluebird Bio Inc.; Celgene Corporation; Sorrento Therapeutics; Fate Therapeutics; and Celyad Oncology among others

The CAR t-cell therapy segment dominated the global t-cell therapy market

The CAR t-cell therapy market was pegged at US$ 5.3 Billion in 2021.

The CAGR of the t-cell therapy market is estimated to be 19.1% during the forecasting period.

Table of Content

  1. INTRODUCTION
    1. Market Ecosystem
    2. Timeline Under Consideration
      1. Historical Years – 2020
      2. Base Year – 2021
      3. Forecast Years – 2022 to 2030
    3. Currency Used in the Report
  2. RESEARCH METHODOLOGY 
    1. Research Approach
    2. Data Collection Methodology
    3. Data Sources
      1. Secondary Sources 
      2. Primary Sources 
    4. Market Estimation Approach
      1. Bottom Up 
      2. Top Down 
    5. Market Forecasting Model
    6. Limitations and Assumptions
  3. PREMIUM INSIGHTS
    1. Current Market Trends (COVID-19 Perspective)
    2. Key Players & Competitive Positioning (2021) 
  4. MARKET DYNAMICS
    1. Drivers
    2. Restraints/Challenges
    3. Opportunities
  5. GLOBAL T-CELL THERAPY MARKET - ANALYSIS & FORECAST, BY TYPE 
    1. CAR T-Cell Therapy
    2. T-Cell Receptor (TCR)-Based
    3. Tumor Infiltrating Lymphocytes (TIL)-Based
  6. GLOBAL T-CELL THERAPY MARKET - ANALYSIS & FORECAST, BY MODALITY 
    1. Research
    2. Commercialized
  7. GLOBAL T-CELL THERAPY MARKET - ANALYSIS & FORECAST, BY INDICATION
    1. Hematologic Malignancies
      1. Lymphoma
      2. Leukemia
      3. Myeloma
    2. Solid Tumors
      1. Melanoma
      2. Brain & Central Nervous System
      3. Liver Cancer
      4. Others
      5. Others 
  8. GLOBAL T-CELL THERAPY MARKET - ANALYSIS & FORECAST, BY REGION
    1. North America T-Cell Therapy Market
      1. North America T-Cell Therapy Market, by Type
      2. North America T-Cell Therapy Market, by Modality
      3. North America T-Cell Therapy Market, by Indication
      4. North America T-Cell Therapy Market, by Country
        1. U.S.
          1. U.S. T-Cell Therapy Market, by Type
          2. U.S. T-Cell Therapy Market, by Modality
          3. U.S. T-Cell Therapy Market, by Indication
        2. Canada
          1. Canada T-Cell Therapy Market, by Type
          2. Canada T-Cell Therapy Market, by Modality
          3. Canada T-Cell Therapy Market, by Indication
    2. Europe T-Cell Therapy Market
      1. Europe T-Cell Therapy Market, by Type
      2. Europe T-Cell Therapy Market, by Modality
      3. Europe T-Cell Therapy Market, by Indication
      4. Europe T-Cell Therapy Market, by Country/Region
        1. Germany
          1. Germany T-Cell Therapy Market, by Type
          2. Germany T-Cell Therapy Market, by Modality
          3. Germany T-Cell Therapy Market, by Indication
        2. U.K.
          1. U.K. T-Cell Therapy Market, by Type
          2. U.K. T-Cell Therapy Market, by Modality
          3. U.K. T-Cell Therapy Market, by Indication
        3. France
          1. France T-Cell Therapy Market, by Type
          2. France T-Cell Therapy Market, by Modality
          3. France T-Cell Therapy Market, by Indication
        4. Spain
          1. Spain T-Cell Therapy Market, by Type
          2. Spain T-Cell Therapy Market, by Modality
          3. Spain T-Cell Therapy Market, by Indication
        5. Italy
          1. Italy T-Cell Therapy Market, by Type
          2. Italy T-Cell Therapy Market, by Modality
          3. Italy T-Cell Therapy Market, by Indication
        6. Rest of Europe 
          1. Rest of Europe T-Cell Therapy Market, by Type
          2. Rest of Europe T-Cell Therapy Market, by Modality
          3. Rest of Europe T-Cell Therapy Market, by Indication
    3. Asia Pacific T-Cell Therapy Market
      1. Asia Pacific T-Cell Therapy Market, by Type
      2. Asia Pacific T-Cell Therapy Market, by Modality
      3. Asia Pacific T-Cell Therapy Market, by Indication
      4. Asia Pacific T-Cell Therapy Market, by Country/Region
        1. China
          1. China T-Cell Therapy Market, by Type
          2. China T-Cell Therapy Market, by Modality
          3. China T-Cell Therapy Market, by Indication
        2. Japan
          1. Japan T-Cell Therapy Market, by Type
          2. Japan T-Cell Therapy Market, by Modality
          3. Japan T-Cell Therapy Market, by Indication
        3. India
          1. India T-Cell Therapy Market, by Type
          2. India T-Cell Therapy Market, by Modality
          3. India T-Cell Therapy Market, by Indication
        4. South Korea
          1. South Korea T-Cell Therapy Market, by Type
          2. South Korea T-Cell Therapy Market, by Modality
          3. South Korea T-Cell Therapy Market, by Indication
        5. Australia
          1. Australia T-Cell Therapy Market, by Type
          2. Australia T-Cell Therapy Market, by Modality
          3. Australia T-Cell Therapy Market, by Indication
        6. Rest of Asia Pacific
          1. Rest of Asia Pacific T-Cell Therapy Market, by Type
          2. Rest of Asia Pacific T-Cell Therapy Market, by Modality
          3. Rest of Asia Pacific T-Cell Therapy Market, by Indication
    4. Rest of the World T-Cell Therapy Market
      1. Rest of the World T-Cell Therapy Market, by Type
      2. Rest of the World T-Cell Therapy Market, by Modality
      3. Rest of the World T-Cell Therapy Market, by Indication
      4. Rest of the World T-Cell Therapy Market, by Region
        1. Latin America
          1. Latin America T-Cell Therapy Market, by Type
          2. Latin America T-Cell Therapy Market, by Modality
          3. Latin America World T-Cell Therapy Market, by Indication
        2. Middle East & Africa
          1. Middle East & Africa T-Cell Therapy Market, by Type
          2. Middle East & Africa T-Cell Therapy Market, by Modality
          3. Middle East & Africa T-Cell Therapy Market, by Indication
  9. COMPANY PROFILES
    1. Novartis AG
      1. Business Snapshot
      2. Products Offered
      3. Financial Details*
      4. Strategic Development
    2. Merck KGaA
    3. Gilead Sciences Inc.
    4. Bristol-Myers Squibb Company
    5. Pfizer Inc.
    6. TCR2 Therapeutics Inc.
    7. Amgen, Inc.
    8. Bluebird Bio Inc.
    9. Celgene Corporation
    10. Sorrento Therapeutics
    11. Fate Therapeutics
    12. Celyad Oncology

*Insights on financial performance are subject to the availability of information in the public domain

List of Tables

 

  1. Global T-Cell Therapy Market, by Type, 2020-2030 (US$ Million)
  2. Global T-Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
  3. Global T-Cell Therapy Market, by Indication, 2020–2030 (US$ Million) 
  4. Global T-Cell Therapy Market, by Region, 2020-2030 (US$ Million) 
  5. North America T-Cell Therapy Market, by Type, 2020-2030 (US$ Million) 
  6. North America T-Cell Therapy Market, by Modality, 2020-2030 (US$ Million) 
  7. North America T-Cell Therapy Market, by Indication, 2020–2030 (US$ Million)
  8. North America T-Cell Therapy Market, by Country, 2020-2030 (US$ Million) 
  9. U.S. T-Cell Therapy Market, by Type, 2020-2030 (US$ Million) 
  10. U.S. T-Cell Therapy Market, by Modality, 2020-2030 (US$ Million) 
  11. U.S. T-Cell Therapy Market, by Indication, 2020–2030 (US$ Million) 
  12. Canada T-Cell Therapy Market, by Type, 2020-2030 (US$ Million) 
  13. Canada T-Cell Therapy Market, by Modality, 2020-2030 (US$ Million) 
  14. Canada T-Cell Therapy Market, by Indication, 2020–2030 (US$ Million) 
  15. Europe T-Cell Therapy Market, by Type, 2020-2030 (US$ Million) 
  16. Europe T-Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
  17. Europe T-Cell Therapy Market, by Indication, 2020–2030 (US$ Million) 
  18. Europe T-Cell Therapy Market, by Country/ Region, 2020-2030 (US$ Million) 
  19. Germany T-Cell Therapy Market, by Type, 2020-2030 (US$ Million) 
  20. Germany T-Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
  21. Germany T-Cell Therapy Market, by Indication, 2020–2030 (US$ Million) 
  22. U.K. T-Cell Therapy Market, by Type, 2020-2030 (US$ Million) 
  23. U.K. T-Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
  24. U.K. T-Cell Therapy Market, by Indication, 2020–2030 (US$ Million) 
  25. France T-Cell Therapy Market, by Type, 2020-2030 (US$ Million) 
  26. France T-Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
  27. France T-Cell Therapy Market, by Indication, 2020–2030 (US$ Million) 
  28. Italy T-Cell Therapy Market, by Type, 2020-2030 (US$ Million) 
  29. Italy T-Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
  30. Italy T-Cell Therapy Market, by Indication, 2020–2030 (US$ Million) 
  31. Spain T-Cell Therapy Market, by Type, 2020-2030 (US$ Million) 
  32. Spain T-Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
  33. Spain T-Cell Therapy Market, by Indication, 2020–2030 (US$ Million) 
  34. Rest of Europe T-Cell Therapy Market, by Type, 2020-2030 (US$ Million)
  35. Rest of Europe T-Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
  36. Rest of Europe T-Cell Therapy Market, by Indication, 2020–2030 (US$ Million) 
  37. Asia Pacific T-Cell Therapy Market, by Type, 2020-2030 (US$ Million) 
  38. Asia Pacific T-Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
  39. Asia Pacific T-Cell Therapy Market, by Indication, 2020–2030 (US$ Million) 
  40. Asia Pacific T-Cell Therapy Market, by Country/ Region, 2020-2030 (US$ Million) 
  41. China T-Cell Therapy Market, by Type, 2020-2030 (US$ Million)
  42. China T-Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
  43. China T-Cell Therapy Market, by Indication, 2020–2030 (US$ Million) 
  44. Japan T-Cell Therapy Market, by Type, 2020-2030 (US$ Million)
  45. Japan T-Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
  46. Japan T-Cell Therapy Market, by Indication, 2020–2030 (US$ Million) 
  47. India T-Cell Therapy Market, by Type, 2020-2030 (US$ Million)
  48. India T-Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
  49. India T-Cell Therapy Market, by Indication, 2020–2030 (US$ Million) 
  50. South Korea T-Cell Therapy Market, by Type, 2020-2030 (US$ Million) 
  51. South Korea T-Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
  52. South Korea T-Cell Therapy Market, by Indication, 2020–2030 (US$ Million) 
  53. Australia T-Cell Therapy Market, by Type, 2020-2030 (US$ Million)
  54. Australia T-Cell Therapy Market, by Modality, 2020-2030 (US$ Million) 
  55. Australia T-Cell Therapy Market, by Indication, 2020–2030 (US$ Million) 
  56. Rest of Asia Pacific T-Cell Therapy Market, by Type, 2020-2030 (US$ Million) 
  57. Rest of Asia Pacific T-Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
  58. Rest of Asia Pacific T-Cell Therapy Market, by Indication, 2020–2030 (US$ Million) 
  59. Rest of the World T-Cell Therapy Market, by Type, 2020-2030 (US$ Million) 
  60. Rest of the World T-Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
  61. Rest of the World T-Cell Therapy Market, by Indication, 2020–2030 (US$ Million) 
  62. Rest of the World T-Cell Therapy Market, by Region, 2020-2030 (US$ Million) 
  63. Latin America T-Cell Therapy Market, by Type, 2020-2030 (US$ Million) 
  64. Latin America T-Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
  65. Latin America T-Cell Therapy Market, by Indication, 2020–2030 (US$ Million) 
  66. Middle East and Africa T-Cell Therapy Market, by Type, 2020-2030 (US$ Million) 
  67. Middle East and Africa T-Cell Therapy Market, by Modality, 2020-2030 (US$ Million) 
  68. Middle East and Africa T-Cell Therapy Market, by Indication, 2020–2030 (US$ Million) 

List of Figures

 

  1. T-Cell Therapy Market Ecosystem  
  2. Snapshot of Global T-Cell Therapy Market, 2020-2030 
  3. Snapshot of Global T-Cell Therapy Market, by Region, 2020-2030 
  4. Global T-Cell Therapy Market: COVID-19 Pandemic Impact Assessment 
  5. Global T-Cell Therapy Market: Key Players & Competitive Positioning (2021) 
  6. T-Cell Therapy: Market Dynamics 
  7. Global Car T-Cell Based T-Cell Therapy Market, 2020-2030 (US$ Million) 
  8. Global T-Cell Receptor (TCR)-Based T-Cell Therapy Market, 2020-2030 (US$ Million) 
  9. Global Tumor Infiltrating Lymphocytes (TIL)-Based T-Cell Therapy Market, 2020-2030 (US$ Million) 
  10. Global T-Cell Therapy Market for Research, 2020-2030 (US$ Million) 
  11. Global T-Cell Therapy Market for Commercialized, 2020-2030 (US$ Million) 
  12. Global T-Cell Therapy Market for Hematologic Malignancies, 2020-2030 (US$ Million)
  13. Global Lymphoma in T-Cell Therapy Market for Hematologic Malignancies, 2020-2030 (US$ Million)
  14. Global Leukemia in T-Cell Therapy Market for Hematologic Malignancies, 2020-2030 (US$ Million)
  15. Global Myeloma in T-Cell Therapy Market for Hematologic Malignancies, 2020-2030 (US$ Million)
  16. Global T-Cell Therapy Market for Solid Tumors, 2020-2030 (US$ Million) 
  17. Global Melanoma in T-Cell Therapy Market for Solid Tumors, 2020-2030 (US$ Million) 
  18. Global Brain & Central Nervous System in T-Cell Therapy Market for Solid Tumors, 2020-2030 (US$ Million) 
  19. Global Liver Cancer in T-Cell Therapy Market for Solid Tumors, 2020-2030 (US$ Million) 
  20. Global Others in T-Cell Therapy Market for Solid Tumors, 2020-2030 (US$ Million) 
  21. Global T-Cell Therapy Market for Others, 2020-2030 (US$ Million) 
  22. North America T-Cell Therapy Market, 2020-2030 (US$ Million) 
  23. U.S. T-Cell Therapy Market, 2020-2030 (US$ Million) 
  24. Canada T-Cell Therapy Market, 2020-2030 (US$ Million) 
  25. Europe T-Cell Therapy Market, 2020-2030 (US$ Million) 
  26. Germany T-Cell Therapy Market, 2020-2030 (US$ Million) 
  27. U.K. T-Cell Therapy Market, 2020-2030 (US$ Million) 
  28. France T-Cell Therapy Market, 2020-2030 (US$ Million) 
  29. Italy T-Cell Therapy Market, 2020-2030 (US$ Million) 
  30. Spain T-Cell Therapy Market, 2020-2030 (US$ Million) 
  31. Rest of Europe T-Cell Therapy Market, 2020-2030 (US$ Million) 
  32. Asia Pacific T-Cell Therapy Market, 2020-2030 (US$ Million) 
  33. China T-Cell Therapy Market, 2020-2030 (US$ Million) 
  34. Japan T-Cell Therapy Market, 2020-2030 (US$ Million) 
  35. India T-Cell Therapy Market, 2020-2030 (US$ Million) 
  36. South Korea T-Cell Therapy Market, 2020-2030 (US$ Million) 
  37. Australia T-Cell Therapy Market, 2020-2030 (US$ Million) 
  38. Rest of Asia Pacific T-Cell Therapy Market, 2020-2030 (US$ Million) 
  39. Rest of the World T-Cell Therapy Market, 2020-2030 (US$ Million) 
  40. Latin America T-Cell Therapy Market, 2020-2030 (US$ Million) 
  41. Middle East & Africa T-Cell Therapy Market, 2020-2030 (US$ Million) 
  42. Novartis AG Revenue from 2018-2021 (US$ Million)
  43. Merck KGaA Revenue from 2018-2021 (US$ Million)
  44. Gilead Sciences Inc. Revenue from 2018-2021 (US$ Million)
  45. Bristol-Myers Squibb Company Revenue from 2018-2021 (US$ Million)
  46. Pfizer Inc. Revenue from 2018-2021 (US$ Million)
  47. TCR2 Therapeutics Inc. Revenue from 2018-2021 (US$ Million)
  48. Amgen, Inc. Revenue from 2018-2021 (US$ Million)
  49. Bluebird Bio Inc. Revenue from 2018-2021 (US$ Million)
  50. Celgene Corporation Revenue from 2018-2021 (US$ Million)
  51. Sorrento Therapeutics Revenue from 2018-2021 (US$ Million)
  52. Fate Therapeutics Revenue from 2018-2021 (US$ Million)
  53. Celyad Oncology Revenue from 2018-2021 (US$ Million)

Single User License
Single User License
Multi User License
Enterprise User License
$4,750.00
Provides access to one user only and should not be shared with other employees within the organization.
Provides access to up to five users within the department or an organization.
Provides access to all the employees in the organization. The report can also be shared with subsidiaries, sister concerns and group entities.
Grants user/users’ access to quantitative data only, which includes but is not restricted to numeric data, tables, and charts as defined by Growth+ Reports.

Using the fundamental research and knowledge services capabilities of GRG Health, Growth Plus Reports may now be tailored based on client needs.

GRG Health's unique GrowthMIX strategy and comprehensive research methodology enable us to provide unique and valuable insights to our clients while uncovering trends that would not be discovered using traditional techniques.

sans

Snehal Deshmukh

Principle Consultant

Speak to analyst